Interleukin inhibitor-related pancreatitis.

Reference 1 Interleukin inhibitors and the possible risk of pancreatitis Internet Document: 9 May 2023. At a March 2023 meeting, the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) asked the Medicines Adverse Reaction Committee (MARC) to consider if there was evidence for an association between the interleukin 6 inhibitor tocilizumab and pancreatitis, and whether pancreatitis could be a class effect for all interleukin inhibitors. The MARC did not consider there was strong evidence of an association between all interleukin inhibitors and pancreatitis, but recommended that Medsafe publish a monitoring communication to encourage reporting of any cases of pancreatitis which may have been associated with a interleukin inhibitor to the Centre for Adverse Reactions Monitoring (CARM). [Extracted from the article]